Closed Solicitations

Drug Treatment for Traumatic Brain Injury (DTTBI)

The Medical Technology Enterprise Consortium (MTEC) announced a Request for Project Proposals (RPP) focused on Drug Treatment for Traumatic Brain Injury (DTTBI) – to rapidly advance the development of TBI drug candidate prototypes, through focused Phase 2 clinical trial testing, to produce a TBI drug that has been fully characterized and ready for Phase 3 trial. The end goal of DTTBI is a commercial TBI drug product that is approved by the U.S. Food and Drug Administration (FDA) to treat moderate – severe TBI.

Prototype Solutions for Peripheral Nerve Injury

The Medical Technology Enterprise Consortium (MTEC) announced a Request for Project Proposals (RPP) focused on providing innovative solutions to a critical problem in muscle denervation. The overarching goal of this program is to provide biomanufacturing or advanced development for an emerging area of medical technology and innovation that supports standard procedures toward a prototype aimed to maintain, re-establish or regenerate myoneural connections.

Prototype Solutions for Optic Nerve Injury

The Medical Technology Enterprise Consortium (MTEC) announced a Request for Project Proposals (RPP) focused on providing innovative solutions to critical problems in visual loss. The overarching goal of this program is to provide biomanufacturing or advanced development for an emerging area of medical technology and innovation that supports standard procedures toward a prototype aimed to re-establish or regenerate damaged visual pathways.


Drug Treatment for Traumatic Brain Injury (DTTBI)

The Medical Technology Enterprise Consortium (MTEC) posted this announcement for a Request for Project Information (RPI) focused on Drug Treatment for Traumatic Brain Injury (DTTBI) to rapidly advance the development of TBI drug candidate prototypes, through focused Phase 2 clinical trial testing, to produce a TBI drug that has been fully characterized and ready for Phase 3 trial. The end goal of DTTBI is a commercial TBI drug product that is approved by the U.S. Food and Drug Administration (FDA) to treat moderate – severe TBI.


 

Model Use of Innovative MEDLOG Data Management Technologies and Industry Best Practices: Architecture, Data Transactions Model and Prototype for a Highly Scalable, Integrated, And Just in Time Defense Medical Logistics Enterprise to support Next Gen Theater/Operational Medicine

The Medical Technology Enterprise Consortium (MTEC) posted this announcement for a Request for Project Proposals (RPP) focused on the performance of an in-depth analysis of current industry/organization MEDICAL LOGISTICS best practices, future trends and technical capabilities, and rapidly emerging technologies, such as blockchain, predictive inventory and asset positioning, placement and location tracking as well as other advanced technologies that can augment current capabilities. The end goal of the analysis is to improve Defense Medical Logistics Information Technology systems to support the provisioning of the highest caliber of medical care to wounded, injured and ill soldiers, sailors, airmen and marines, enhancing the mission readiness and effectiveness of care for military personnel.


Multi-Topic

This Request for Project Proposals (RPP) was aimed to solicit white papers from prospective and current MTEC members for a broad range of medical technological solutions related to the following Technology Focus Areas:

  1. Prevention, Diagnosis and Treatment of Infectious Diseases
  2. Care of Combat Casualties
  3. Clinical and Rehabilitative Medicine
  4. Military Operational Medicine
  5. Medical Simulation and Information Sciences
  6. Advanced Medical Technologies
  7. Advanced Medical Regulatory and Manufacturing Technologies

We have begun receiving feedback on some of the Multi-Topic White Papers. Due to the significant number of submissions MTEC received, the following Multi-Topic timeline provides an updated forecast for completing the remaining steps. Please be aware that not all funding sponsors will follow the same solicitation process following the reviews. For example, sponsors can decide whether to request a small project proposal, solutions brief, or large project proposal.

Each of these processes will follow a somewhat different timeline. Timeline dates are subject to change.

White Papers due – 31 October 2017
White Papers evaluated – 1 November 2017 – 28 February 2018
Notification to Offerors (invited to propose/not invited) – in progress as of 1 March 2018
Feedback to Members – estimated completion on or before 30  March 2018

There is no date for when awards must be made.

 


Systems Biology

The Medical Technology Enterprise Consortium (MTEC) was excited to announce a Request for Project Information (RPI) focused on the use of systems biology approaches to: i) better understand drug-resistant infectious diseases at their molecular, cellular, and systems levels, and ii) identify new potential products and develop them into prototypes for the diagnosis and treatment of these diseases. MTEC’s systems biology initiative is focused on utilizing an integrative rather than reductionist approach to understand how biological systems function and interact as a whole. The goal of this initiative is to design an integrated and collaborative research and prototype development portfolio leveraging known or emerging knowledge of the regulatory processes of resistance mechanisms with the purpose of integrated validation, and prototype development with follow-on translation into clinical use.


Combating Antibiotic Resistant Bacteria (CARB) Request for Project Information

The use of antibiotics saves millions of lives each year around the world. Unfortunately indiscriminant use and lack of compliance with treatment guidelines have led to conditions for accumulation of mutations in bacteria that have caused drug resistance, resulting in a significant decrease in the number of available drugs effective to treat both rare and common bacterial infections. The rise in antibiotic resistance threatens various aspects of life, including both human and animal health, the agriculture industry, the economy, and the treatment of post-surgical infection from elective and life-saving medical procedures. Therefore, there is a critical need to develop novel antibiotics, other therapeutics, and, vaccines to combat infection by antibiotic-resistant bacteria and improve medical surveillance and diagnostic tests for the identification and characterization of antibiotic-resistant bacteria. Advancement in these areas will hopefully make a major impact by strengthening national and international healthcare for humans and animals, public health, agriculture practices, food safety, and research, development and manufacturing.


Dengue Human Infection Model (DHIM)

MTEC announced a solicitation focused on accelerating ongoing development by USAMRMC of a dengue human infection model (DHIM) regulated by the U.S. Food and Drug Administration (FDA) that aims to safely and reproducibly create uncomplicated dengue infections in human volunteers using live, attenuated, well-characterized dengue virus (DENV) challenge material.  The DHIM will be achieved when each of the four DENV challenge strains (serotypes 1-4) is characterized via FDA Phase 1 clinical studies.


Brain Machine Interface Prototype Development for Vision Restoration (BMI)

MTEC announced a solicitation focused on the clinical, prototyping, and manufacturing needs to develop a visual prosthesis that addresses capability gaps for vision restoration and rehabilitation. Specifically, this research opportunity seeks to develop an innovative solution for prototyping an appropriate brain-machine interface.


Regenerative Medicine (Regen)

Research focused on support areas of regenerative medicine manufacturing and prototyping that require development and harmonization into reproducible, consistent procedures which could stand the test of U.S. Food and Drug Administration (FDA) approval. This emerging area of medical technology and innovation suffers from the lack of standard manufacturing procedures that support this combination product line. This initiative is intended to have a period of performance of up to 5 years. Outcomes from this award are anticipated to result in well-defined and sufficiently advanced prototypes and manufacturing that may be included in regulatory applications seeking FDA approval.

Proposals were sought in five categories of potential areas of improvements. MTEC believes all of these areas currently present roadblocks to regenerative medicine prototype development and product manufacturing that will need to be addressed over the life span of the funding. These are as follows:

  • Development of universal, defined culture media for regenerative medicine;
  • Bioreactors to enable efficient and cost-effective cell and tissue expansion for regenerative medicine products;
  • Cell, tissue, and product preservation for regenerative and personalized medicine;
  • Large scale manufacturing and quality control of RM-based products;
  • Dynamic and innovative quality control for regenerative medicine manufacturing.